Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lyfe Rx vs Nucific

Lyfe Rx
Graded #375

Higher grade

vs+2.0999999999999943
Nucific
Graded #417

Lower grade

The verdict

Lyfe Rx takes it — 58.3/100 to 56.2/100.

Lyfe Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lyfe Rx offers compounded semaglutide ($289) and compounded tirzepatide ($399).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLyfe Rx +5
50
45
Dose & formulationLyfe Rx +11
64
53
Clinical oversightNucific +9
67
76
Labs & monitoringEven
52
52
FulfillmentNucific +5
62
67
Contract termsLyfe Rx +14
55
41
Lyfe Rx · left barNucific · right bar

The numbers

MetricLyfe RxNucific
WeighScore58.3/10056.2/100
GradeCC
Scorecard rank#375#417
Semaglutide$225/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Lyfe Rx

Graded #375 · C

Strengths

  • Both compounded semaglutide and tirzepatide available
  • Delivery to all 50 states with 1–3 day pharmacy turnaround

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • Also sells non-prescription supplements ('Tirzepatide Weight Loss Supplement', 'Lipo Burn')
  • Shopify-based e-commerce storefront — less clinical infrastructure
  • FDA issued this company a warning letter dated 9 September 2025; the letter is public in FDA's warning-letter database
Nucific

Graded #417 · C

Strengths

  • Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
  • Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
  • Discloses that featured patients were compensated for their time
  • Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
  • Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue

Where it loses points

  • No price is published anywhere; every option is gated behind a three-minute quiz
  • The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
  • A BBB Accredited A+ claim is displayed without a link to the BBB profile
  • No state list and no named pharmacy, only licensed U.S. pharmacies
  • Before-and-after photographs are used alongside compensated testimonials

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard